Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Core Viewpoint - Moleculin Biotech, Inc. has announced a securities purchase agreement for a registered direct offering and concurrent private placement, aiming to raise approximately $3.5 million for working capital and corporate purposes [1][2]. Group 1: Offering Details - The company will sell 3,271,029 shares of common stock (or pre-funded warrants) at a price of $1.07 per share, along with warrants to purchase up to 6,542,058 additional shares [1]. - The warrants will have an exercise price of $1.07 per share, exercisable upon shareholder approval, and will expire five years from the initial exercise date [1]. - Roth Capital Partners is acting as the exclusive placement agent for the offering, which is expected to close on or about February 26, 2025 [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital and general corporate purposes [2]. Group 3: Company Overview - Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses [6]. - The lead program, Annamycin, is designed to avoid multidrug resistance and cardiotoxicity, currently in development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases [6][7]. - The company is initiating the MIRACLE trial, a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for AML treatment [7]. Group 4: Additional Developments - Moleculin is also developing WP1066, an immune/transcription modulator targeting various cancers, and a portfolio of antimetabolites including WP1122 for potential treatment of pathogenic viruses [8].